Metastatic Breast Cancer (MBC)

Also known as: Metastatic Breast cancer / Metastatic Breast Cancers / Carcinoma breast stage IV / Breast carcinoma NOS stage IV / Breast carcinoma stage IV / Breast cancer stage IV / Breast cancer NOS stage IV / Breast cancer metastatic

DrugDrug NameDrug Description
DB12001AbemaciclibAbemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed after unsuccessful endocrine therapy. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with [DB00947]. Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma.
DB01217AnastrozoleAnastrozole is a drug indicated in the treatment of breast cancer in post-menopausal women. It is used both in adjuvant therapy (i.e. following surgery) and in metastatic breast cancer. It decreases the amount of estrogens that the body makes. Anastrozole belongs in the class of drugs known as aromatase inhibitors. It inhibits the enzyme aromatase, which is responsible for converting androgens (produced by women in the adrenal glands) to estrogens.
DB00112BevacizumabA recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.
DB01101CapecitabineCapecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
DB00958CarboplatinAn organoplatinum compound that possesses antineoplastic activity. [PubChem]
DB01248DocetaxelDocetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.
DB00997DoxorubicinDoxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.
DB00783EstradiolEstradiol (also known as E2 or 17β-estradiol) is a naturally occurring hormone that circulates endogenously within the human body. It is the most potent form of mammalian estrogenic steroids and acts as the major female sex hormone. As such, estradiol plays an essential role in the regulation of the menstrual cycle, in the development of puberty and secondary female sex characteristics, as well as in ageing and several hormonally-mediated disease states. Estrogen mediates its effects across the body through potent agonism of the Estrogen Receptor (ER), which is located in various tissues including in the breasts, uterus, ovaries, skin, prostate, bone, fat, and brain. Estradiol binds to both subtypes of the Estrogen Receptor: Estrogen Receptor Alpha (ERα) and Estrogen Receptor Beta (ERβ). Estradiol also acts as a potent agonist of G Protein-coupled Estrogen Receptor (GPER), which has recently been recognized as a major mediator of estradiol's rapid cellular effects [A31620]. Estradiol is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen production such as menopausal and peri-menopausal symptoms as well as hypoestrogenism. It is also used in transgender hormone therapy, as a component of oral contraceptive pills for preventing pregnancy (most commonly as [DB00977], a synthetic form of estradiol), and is sometimes used for the palliative treatment of some hormone-sensitive cancers like breast and prostate cancer. Estradiol is available in a number of formulations including oral, transdermal, and injectable. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. However, after menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus, estrone and the sulphate conjugated form, estrone sulphate, are the most abundant circulating estrogens in postmenopausal women [FDA Label]. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol at the receptor level. Because of the difference in potency between estradiol and estrone, menopause (and a change in primary hormone from estradiol to estrone) is associated with a number of symptoms associated with this reduction in potency and in estrogenic effects. These include hot flashes, vaginal dryness, mood changes, irregular menses, chills, and sleeping problems. When used for oral or IM administration, estradiol is commonly synthesized as a pro-drug ester (such as [DB13952], [DB13953], [DB13954], [DB13955], and [DB13956]). It is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%). First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter the systemic circulation and exert its estrogenic effects [A12102]. Esterification of estradiol aims to improve absorption after oral administration (such as with Estradiol valerate) or to sustain release from intramuscular depot injections (such as with Estradiol Cypionate) through improved lipophilicity [T84]. Following absorption, the esters are cleaved, resulting in the release of endogenous estradiol, or 17β-estradiol. Recommendations for treatment of menopausal symptoms changed drastically following the release of results and early termination of the Women's Health Initiative (WHI) studies in 2002 as a number of concerns were raised regarding the use of estrogen [A31626]. Specifically, the combined estrogen–progestin arm was discontinued after approximately five years of follow up due to a statistically significant increase in invasive breast cancer and in cardiovascular events [A31627]. Following extensive critique of the WHI results in the years following its release, Hormone Replacement Therapy (HRT) is now recommended to be used only for a short period (for 3-5 years post-menopause) in low doses, and in women without a history of breast cancer or at increased risk of cardiovascular or thromboembolic disease [A31628]. Notably, use of estrogen for menopausal symptoms should always be accompanied by a progestin component due to estrogen's effects on the endometrium; in women with an intact uterus, unopposed estrogen has been shown to promote the growth of the endometrium which can lead to endometrial hyperplasia and possibly cancer in the long-term. [DB00977] (EE) is a synthetic form of estradiol commonly used as the estrogenic component of most combination Oral Contraceptive Pills (OCPs). Ethinyl Estradiol differs from Estradiol in that it has improved biovailability and greater resistance to metabolism, making it more suitable for oral administration.
DB09381Estrogens, esterifiedEsterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of menopause such as hot flashes, vaginal dryness, vaginal burning or irritation, or other hormonal changes in the vagina. It is being also for the prevention and treatment of osteoporosis.
DB04845IxabepiloneIxabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation.
DB01259LapatinibLapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug Capecitabine. Lapatinib is human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
DB06710MethyltestosteroneA synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methyltestosterone is a schedule III drug in the US.
DB01204MitoxantroneAn anthracenedione-derived antineoplastic agent. [PubChem]
DB09074OlaparibOlaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death. Olaparib is available as oral tablets marketed under the brand name Lynparza and was initially indicated as a maintenance therapy or monotherapy for the treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. On January 12, 2018, FDA expanded the approved use of Lynparza to include chemotherapy-experienced patients with germline breast cancer susceptibility gene (BRCA) mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. In a randomized clinical trial involving patients with HER2-negative metastatic breast cancer with a germline BRCA mutation, the median progression-free survival for patients taking Lynparza was 7 months compared to 4.2 months for patients taking chemotherapy only. Patient selection for this newly-approved indication can be performed based on an FDA-approved genetic test, called the BRACAnalysis CDx.
DB01229PaclitaxelPaclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. When it was developed commercially by Bristol-Myers Squibb (BMS), the generic name was changed to paclitaxel and the BMS compound is sold under the trademark Taxol. In this formulation, paclitaxel is dissolved in Kolliphor EL and ethanol, as a delivery agent. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane. [Wikipedia]
DB09073PalbociclibPalbociclib is an oral, reversible, selective, small-molecule inhibitor of CDK4 and CDK6 indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. CDK4 and CDK6 along with their regulatory partner cyclin D1 play a key role in regulating the G1- to S-phase cell-cycle transition via regulation of phosphorylation of the retinoblastoma (Rb) protein. Inhibition of these proteins leads to reduced phosphorylation of Rb, inhibition of downstream signalling, and increased tumor growth arrest. Palbociclib received an accelerated approval from the Food and Drug Administration on February 3, 2015.
DB06366PertuzumabPertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. FDA approved June 8, 2012.
DB11730RibociclibRibociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.
DB00675TamoxifenOne of the selective estrogen receptor modulators (SERM) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the endometrium.
DB00539ToremifeneA first generation nonsteroidal selective estrogen receptor modulator (SERM) that is structurally related to tamoxifen. Like tamoxifen, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue. [PubChem]
DB00072TrastuzumabA recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein. Produced in CHO cell culture. In December 2017, FDA approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). It displays biosimilar properties as Herceptin according to clinical data. While Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer, it is the second biosimilar approved in the U.S. for the treatment of cancer.
DB00361VinorelbineVinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) [L1998]. It was initially approved in the USA in 1990's for the treatment of NSCLC [L2010]. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting [A32347]. A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug [L2002].
DrugDrug NameTargetType
DB12001AbemaciclibMultidrug and toxin extrusion protein 1transporter
DB12001AbemaciclibMultidrug and toxin extrusion protein 2transporter
DB12001AbemaciclibCyclin-dependent kinase 4target
DB12001AbemaciclibCyclin-dependent kinase 6target
DB12001AbemaciclibSerum albumincarrier
DB12001Abemaciclibalpha1-acid glycoproteincarrier
DB12001AbemaciclibCytochrome P450 3A4enzyme
DB12001AbemaciclibOrnithine carbamoyltransferase, mitochondrialtransporter
DB12001AbemaciclibMultidrug resistance protein 1transporter
DB12001AbemaciclibATP-binding cassette sub-family G member 2transporter
DB01217AnastrozoleCytochrome P450 19A1target
DB01217AnastrozoleCytochrome P450 19A1enzyme
DB01217AnastrozoleCytochrome P450 1A2enzyme
DB01217AnastrozoleCytochrome P450 2C9enzyme
DB01217AnastrozoleCytochrome P450 3A4enzyme
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00112BevacizumabComplement C1r subcomponenttarget
DB00112BevacizumabComplement C1q subcomponent subunit Atarget
DB00112BevacizumabComplement C1q subcomponent subunit Btarget
DB00112BevacizumabComplement C1q subcomponent subunit Ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00112BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabVascular endothelial growth factor Atarget
DB01101CapecitabineThymidylate synthasetarget
DB01101CapecitabineThymidine phosphorylaseenzyme
DB01101CapecitabineCytidine deaminaseenzyme
DB01101CapecitabineLiver carboxylesterase 1enzyme
DB01101CapecitabineDihydropyrimidine dehydrogenase [NADP(+)]enzyme
DB01101CapecitabineCytochrome P450 2C9enzyme
DB01101CapecitabineDNAtarget
DB01101CapecitabineRNAtarget
DB00958CarboplatinDNAtarget
DB00958CarboplatinHigh affinity copper uptake protein 1transporter
DB00958CarboplatinProbable low affinity copper uptake protein 2transporter
DB00958CarboplatinXanthine dehydrogenase/oxidaseenzyme
DB00958CarboplatinMyeloperoxidaseenzyme
DB00958CarboplatinGlutathione S-transferase theta-1enzyme
DB00958CarboplatinMetallothionein-1Aenzyme
DB00958CarboplatinMetallothionein-2enzyme
DB00958CarboplatinSuperoxide dismutase [Cu-Zn]enzyme
DB00958CarboplatinGlutathione S-transferase Penzyme
DB00958CarboplatinGlutathione S-transferase Mu 1enzyme
DB00958CarboplatinNAD(P)H dehydrogenase [quinone] 1enzyme
DB00958CarboplatinCopper-transporting ATPase 1transporter
DB00958CarboplatinCopper-transporting ATPase 2transporter
DB00958CarboplatinATP-binding cassette sub-family G member 2transporter
DB00958CarboplatinCanalicular multispecific organic anion transporter 1transporter
DB01248DocetaxelApoptosis regulator Bcl-2target
DB01248DocetaxelTubulin beta-1 chaintarget
DB01248DocetaxelCytochrome P450 3A4enzyme
DB01248DocetaxelCytochrome P450 3A5enzyme
DB01248DocetaxelCytochrome P450 3A7enzyme
DB01248DocetaxelMultidrug resistance protein 1transporter
DB01248DocetaxelMultidrug resistance-associated protein 7transporter
DB01248DocetaxelCytochrome P450 1B1enzyme
DB01248DocetaxelMicrotubule-associated protein 2target
DB01248DocetaxelMicrotubule-associated protein 4target
DB01248DocetaxelMicrotubule-associated protein tautarget
DB01248DocetaxelSolute carrier organic anion transporter family member 1B3transporter
DB01248DocetaxelSolute carrier family 22 member 7transporter
DB01248DocetaxelATP-binding cassette sub-family G member 2transporter
DB01248DocetaxelCanalicular multispecific organic anion transporter 1transporter
DB01248DocetaxelMultidrug resistance-associated protein 1transporter
DB01248DocetaxelNuclear receptor subfamily 1 group I member 2target
DB00997DoxorubicinDNA topoisomerase 2-alphatarget
DB00997DoxorubicinDNAtarget
DB00997DoxorubicinCytochrome P450 3A4enzyme
DB00997DoxorubicinCytochrome P450 2D6enzyme
DB00997DoxorubicinCytochrome P450 2B6enzyme
DB00997DoxorubicinMultidrug resistance protein 1transporter
DB00997DoxorubicinCanalicular multispecific organic anion transporter 2transporter
DB00997DoxorubicinMultidrug resistance-associated protein 6transporter
DB00997DoxorubicinMultidrug resistance-associated protein 1transporter
DB00997DoxorubicinMultidrug resistance-associated protein 7transporter
DB00997DoxorubicinATP-binding cassette sub-family G member 2transporter
DB00997DoxorubicinBile salt export pumptransporter
DB00997DoxorubicinSolute carrier family 22 member 16transporter
DB00997DoxorubicinATP-binding cassette sub-family B member 8, mitochondrialtransporter
DB00997DoxorubicinCytochrome P450 1B1enzyme
DB00997DoxorubicinCarbonyl reductase [NADPH] 1enzyme
DB00997DoxorubicinCarbonyl reductase [NADPH] 3enzyme
DB00997DoxorubicinAlcohol dehydrogenase [NADP(+)]enzyme
DB00997DoxorubicinAldo-keto reductase family 1 member C3enzyme
DB00997DoxorubicinNAD(P)H dehydrogenase [quinone] 1enzyme
DB00997DoxorubicinXanthine dehydrogenase/oxidaseenzyme
DB00997DoxorubicinNitric oxide synthase, endothelialenzyme
DB00997DoxorubicinNitric oxide synthase, inducibleenzyme
DB00997DoxorubicinNitric oxide synthase, brainenzyme
DB00997DoxorubicinNADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrialenzyme
DB00997DoxorubicinNADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrialenzyme
DB00997DoxorubicinNADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrialenzyme
DB00997DoxorubicinNADPH--cytochrome P450 reductaseenzyme
DB00997DoxorubicinRalA-binding protein 1transporter
DB00997DoxorubicinCanalicular multispecific organic anion transporter 1transporter
DB00997DoxorubicinSerum albumincarrier
DB00997DoxorubicinNucleolar and coiled-body phosphoprotein 1target
DB00783EstradiolEstrogen receptor alphatarget
DB00783EstradiolNuclear receptor subfamily 1 group I member 2target
DB00783EstradiolSex hormone-binding globulincarrier
DB00783EstradiolEstrogen receptor betatarget
DB00783EstradiolCytochrome P450 1A2enzyme
DB00783EstradiolUDP-glucuronosyltransferase 1-1enzyme
DB00783EstradiolSerum albumincarrier
DB00783EstradiolFatty acid-binding protein, intestinalcarrier
DB00783EstradiolCytochrome P450 3A4enzyme
DB00783EstradiolCytochrome P450 3A5enzyme
DB00783EstradiolCytochrome P450 3A7enzyme
DB00783EstradiolSolute carrier family 22 member 2transporter
DB00783EstradiolSolute carrier family 22 member 1transporter
DB00783EstradiolSolute carrier family 22 member 3transporter
DB00783EstradiolSolute carrier organic anion transporter family member 2B1transporter
DB00783EstradiolSolute carrier organic anion transporter family member 1A2transporter
DB00783EstradiolMultidrug resistance-associated protein 7transporter
DB00783EstradiolSolute carrier family 22 member 11transporter
DB00783EstradiolATP-binding cassette sub-family G member 2transporter
DB00783EstradiolSolute carrier organic anion transporter family member 1B1transporter
DB00783EstradiolMultidrug resistance protein 1transporter
DB00783EstradiolCytochrome P450 1A1enzyme
DB00783EstradiolCytochrome P450 1B1enzyme
DB00783EstradiolCytochrome P450 2C19enzyme
DB00783EstradiolCytochrome P450 2C8enzyme
DB00783EstradiolCytochrome P450 2C9enzyme
DB00783EstradiolSolute carrier family 22 member 8transporter
DB00783EstradiolSolute carrier organic anion transporter family member 1B3transporter
DB00783EstradiolSolute carrier organic anion transporter family member 1C1transporter
DB00783EstradiolSolute carrier organic anion transporter family member 4A1transporter
DB00783EstradiolNeuronal acetylcholine receptor subunit alpha-4target
DB00783EstradiolNuclear receptor coactivator 2target
DB00783EstradiolG-protein coupled estrogen receptor 1target
DB00783EstradiolATP synthase subunit atarget
DB00783EstradiolBeclin-1target
DB00783EstradiolEstradiol 17-beta-dehydrogenase 2target
DB00783EstradiolEstrogen-related receptor gammatarget
DB09381Estrogens, esterifiedCytochrome P450 3A4enzyme
DB04845IxabepiloneTubulin beta-3 chaintarget
DB04845IxabepiloneCytochrome P450 3A4enzyme
DB01259LapatinibEpidermal growth factor receptortarget
DB01259LapatinibReceptor tyrosine-protein kinase erbB-2target
DB01259LapatinibCytochrome P450 3A4enzyme
DB01259LapatinibCytochrome P450 2C8enzyme
DB01259LapatinibMultidrug resistance protein 1transporter
DB01259LapatinibAntigen peptide transporter 1transporter
DB01259LapatinibCytochrome P450 3A5enzyme
DB01259LapatinibCytochrome P450 2C19enzyme
DB06710MethyltestosteroneCytochrome P450 19A1enzyme
DB06710MethyltestosteroneCytochrome P450 2B6enzyme
DB06710MethyltestosteroneCytochrome P450 3A4enzyme
DB06710MethyltestosteroneAndrogen receptortarget
DB06710MethyltestosteroneSolute carrier organic anion transporter family member 1A2transporter
DB06710MethyltestosteroneSolute carrier family 22 member 8transporter
DB06710MethyltestosteroneSerum albumincarrier
DB06710MethyltestosteroneSex hormone-binding globulincarrier
DB06710MethyltestosteroneEstrogen receptor alphatarget
DB01204MitoxantroneDNA topoisomerase 2-alphatarget
DB01204MitoxantroneCytochrome P450 2E1enzyme
DB01204MitoxantroneMultidrug resistance protein 1transporter
DB01204MitoxantroneMultidrug resistance-associated protein 1transporter
DB01204MitoxantroneATP-binding cassette sub-family G member 2transporter
DB01204MitoxantroneDNAtarget
DB01204MitoxantroneCytochrome P450 1B1enzyme
DB01204MitoxantroneCytochrome P450 3A4enzyme
DB09074OlaparibPoly [ADP-ribose] polymerase 1target
DB09074OlaparibCytochrome P450 3A4enzyme
DB09074OlaparibCytochrome P450 2B6enzyme
DB09074OlaparibPoly [ADP-ribose] polymerase 2target
DB09074OlaparibPoly [ADP-ribose] polymerase 3target
DB01229PaclitaxelApoptosis regulator Bcl-2target
DB01229PaclitaxelTubulin beta-1 chaintarget
DB01229PaclitaxelCytochrome P450 2C8enzyme
DB01229PaclitaxelCytochrome P450 3A4enzyme
DB01229PaclitaxelCytochrome P450 3A5enzyme
DB01229PaclitaxelCytochrome P450 3A7enzyme
DB01229PaclitaxelCytochrome P450 2C9enzyme
DB01229PaclitaxelBile salt export pumptransporter
DB01229PaclitaxelMultidrug resistance protein 1transporter
DB01229PaclitaxelMultidrug resistance-associated protein 1transporter
DB01229PaclitaxelMultidrug resistance-associated protein 7transporter
DB01229PaclitaxelCytochrome P450 19A1enzyme
DB01229PaclitaxelCytochrome P450 1B1enzyme
DB01229PaclitaxelSolute carrier organic anion transporter family member 1B3transporter
DB01229PaclitaxelNuclear receptor subfamily 1 group I member 2target
DB01229PaclitaxelMicrotubule-associated protein 4target
DB01229PaclitaxelMicrotubule-associated protein 2target
DB01229PaclitaxelMicrotubule-associated protein tautarget
DB01229PaclitaxelATP-binding cassette sub-family G member 2transporter
DB01229PaclitaxelCanalicular multispecific organic anion transporter 1transporter
DB09073PalbociclibCyclin-dependent kinase 4target
DB09073PalbociclibCyclin-dependent kinase 6target
DB09073PalbociclibCytochrome P450 3A4enzyme
DB09073PalbociclibSulfotransferase 2A1enzyme
DB06366PertuzumabReceptor tyrosine-protein kinase erbB-2target
DB11730RibociclibCyclin-dependent kinase 4target
DB11730RibociclibCyclin-dependent kinase 6target
DB00675TamoxifenEstrogen receptor alphatarget
DB00675TamoxifenEstrogen receptor betatarget
DB00675TamoxifenCytochrome P450 2C9enzyme
DB00675TamoxifenCytochrome P450 3A4enzyme
DB00675TamoxifenCytochrome P450 2D6enzyme
DB00675TamoxifenCytochrome P450 2C8enzyme
DB00675TamoxifenCytochrome P450 2B6enzyme
DB00675TamoxifenLiver carboxylesterase 1enzyme
DB00675TamoxifenCytochrome P450 3A5enzyme
DB00675TamoxifenCytochrome P450 1A1enzyme
DB00675TamoxifenCytochrome P450 1A2enzyme
DB00675TamoxifenCytochrome P450 1B1enzyme
DB00675TamoxifenCytochrome P450 2C19enzyme
DB00675TamoxifenDimethylaniline monooxygenase [N-oxide-forming] 1enzyme
DB00675TamoxifenDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB00675TamoxifenCytochrome P450 3A7enzyme
DB00675TamoxifenMultidrug resistance protein 1transporter
DB00675TamoxifenBile salt export pumptransporter
DB00675TamoxifenATP-binding cassette sub-family G member 2transporter
DB00675TamoxifenCytochrome P450 19A1enzyme
DB00675TamoxifenCytochrome P450 2A6enzyme
DB00675TamoxifenCytochrome P450 2E1enzyme
DB00675TamoxifenUDP-glucuronosyltransferase 1-10enzyme
DB00675TamoxifenSulfotransferase 1A1enzyme
DB00675TamoxifenCanalicular multispecific organic anion transporter 1transporter
DB00675Tamoxifen3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerasetarget
DB00675TamoxifenProtein kinase Ctarget
DB00675TamoxifenAndrogen receptortarget
DB00675TamoxifenPotassium voltage-gated channel subfamily H member 2target
DB00675TamoxifenNuclear receptor subfamily 1 group I member 2target
DB00675TamoxifenEstrogen-related receptor gammatarget
DB00675TamoxifenSex hormone-binding globulintarget
DB00539ToremifeneEstrogen receptor alphatarget
DB00539ToremifeneCytochrome P450 3A4enzyme
DB00539ToremifeneMultidrug resistance protein 1transporter
DB00539ToremifeneCytochrome P450 1A1enzyme
DB00539ToremifeneCytochrome P450 1A2enzyme
DB00539ToremifeneSex hormone-binding globulintarget
DB00072TrastuzumabCytochrome P450 19A1enzyme
DB00072TrastuzumabReceptor tyrosine-protein kinase erbB-2target
DB00072TrastuzumabEpidermal growth factor receptortarget
DB00072TrastuzumabComplement C1r subcomponenttarget
DB00072TrastuzumabComplement C1q subcomponent subunit Atarget
DB00072TrastuzumabComplement C1q subcomponent subunit Btarget
DB00072TrastuzumabComplement C1q subcomponent subunit Ctarget
DB00072TrastuzumabComplement C1s subcomponenttarget
DB00072TrastuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00361VinorelbineTubulin beta chaintarget
DB00361VinorelbineCytochrome P450 3A4enzyme
DB00361VinorelbineMultidrug resistance protein 1transporter
DB00361VinorelbineCytochrome P450 2D6enzyme
DrugDrug NamePhaseStatusCount
DB00112Bevacizumab0Recruiting1
DB11714Durvalumab0Recruiting1
DB08885Aflibercept1Completed1
DB05220Alisertib1Recruiting1
DB12015Alpelisib1Active Not Recruiting1
DB06692Aprotinin1Terminated1
DB09274Artesunate1Completed1
DB00928Azacitidine1Recruiting1
DB06769Bendamustine1Completed1
DB01101Capecitabine1Active Not Recruiting1
DB01101Capecitabine1Completed6
DB01101Capecitabine1Not Yet Recruiting1
DB01101Capecitabine1Terminated1
DB00002Cetuximab1Unknown Status1
DB00169Cholecalciferol1Active Not Recruiting1
DB00515Cisplatin1Recruiting1
DB00531Cyclophosphamide1Completed1
DB00091Cyclosporine1Completed1
DB11651Dactolisib1Completed3
DB01248Docetaxel1Completed2
DB11714Durvalumab1Active Not Recruiting1
DB11841Entinostat1Not Yet Recruiting1
DB00445Epirubicin1Completed2
DB12147Erdafitinib1Recruiting1
DB00153Ergocalciferol1Active Not Recruiting1
DB01590Everolimus1Completed2
DB00990Exemestane1Withdrawn1
DB13034Foxy-51Completed1
DB13034Foxy-51Recruiting1
DB00947Fulvestrant1Recruiting2
DB11962GSK-10596151Terminated1
DB11896Gedatolisib1Recruiting1
DB00441Gemcitabine1Completed1
DB00441Gemcitabine1Recruiting1
DB00014Goserelin1Withdrawn1
DB12672Icaritin1Unknown Status1
DB04845Ixabepilone1Completed1
DB12167LY-30234141Recruiting1
DB01259Lapatinib1Active Not Recruiting1
DB01259Lapatinib1Completed2
DB01259Lapatinib1Terminated1
DB01006Letrozole1Completed1
DB01006Letrozole1Recruiting1
DB12674Lurbinectedin1Completed1
DB00563Methotrexate1Completed1
DB00683Midazolam1Recruiting1
DB09074Olaparib1Completed1
DB05173PTC2991Completed1
DB12638PU-H711Recruiting1
DB01229Paclitaxel1Completed4
DB01229Paclitaxel1Recruiting5
DB13809Paclitaxel poliglumex1Completed1
DB09073Palbociclib1Recruiting1
DB06603Panobinostat1Completed1
DB06589Pazopanib1Terminated1
DB09037Pembrolizumab1Recruiting1
DB00642Pemetrexed1Recruiting1
DB06366Pertuzumab1Recruiting1
DB00780Phenelzine1Recruiting1
DB11663Pictilisib1Completed1
DB05578Ramucirumab1Completed1
DB12614Reparixin1Completed1
DB11730Ribociclib1Recruiting1
DB12376Ricolinostat1Recruiting1
DB11836Sapanisertib1Recruiting1
DB09143Sonidegib1Completed1
DB00398Sorafenib1Completed1
DB12108Taselisib1Recruiting1
DB00853Temozolomide1Completed1
DB00072Trastuzumab1Active Not Recruiting2
DB00072Trastuzumab1Completed4
DB00072Trastuzumab1Recruiting1
DB00072Trastuzumab1Unknown Status1
DB05773Trastuzumab emtansine1Completed2
DB05773Trastuzumab emtansine1Recruiting1
DB11771Tremelimumab1Terminated1
DB06333Trodusquemine1Suspended1
DB05294Vandetanib1Completed1
DB00361Vinorelbine1Completed1
DB00361Vinorelbine1Terminated2
DB11094Vitamin D1Active Not Recruiting1
DB11881AUY9221 / 2Withdrawn1
DB05220Alisertib1 / 2Completed1
DB06263Amrubicin1 / 2Completed1
DB11945Avelumab1 / 2Not Yet Recruiting1
DB05051BZL1011 / 2Completed1
DB01128Bicalutamide1 / 2Recruiting1
DB01101Capecitabine1 / 2Completed1
DB01101Capecitabine1 / 2Terminated1
DB01101Capecitabine1 / 2Withdrawn1
DB00515Cisplatin1 / 2Terminated1
DB00531Cyclophosphamide1 / 2Active Not Recruiting1
DB11651Dactolisib1 / 2Completed1
DB01254Dasatinib1 / 2Active Not Recruiting1
DB01254Dasatinib1 / 2Completed1
DB01248Docetaxel1 / 2Completed2
DB01248Docetaxel1 / 2Terminated1
DB00997Doxorubicin1 / 2Completed1
DB04940Eribulin1 / 2Recruiting2
DB08871Eribulin1 / 2Recruiting3
DB01590Everolimus1 / 2Terminated1
DB00990Exemestane1 / 2Terminated1
DB00441Gemcitabine1 / 2Terminated1
DB00724Imiquimod1 / 2Active Not Recruiting1
DB06169Indibulin1 / 2Unknown Status1
DB04845Ixabepilone1 / 2Completed2
DB04845Ixabepilone1 / 2Withdrawn1
DB01259Lapatinib1 / 2Completed2
DB01259Lapatinib1 / 2Recruiting1
DB01259Lapatinib1 / 2Terminated1
DB01259Lapatinib1 / 2Unknown Status1
DB01006Letrozole1 / 2Active Not Recruiting1
DB05575Motesanib1 / 2Withdrawn1
DB11793Niraparib1 / 2Active Not Recruiting1
DB11793Niraparib1 / 2Not Yet Recruiting1
DB01229Paclitaxel1 / 2Active Not Recruiting3
DB01229Paclitaxel1 / 2Completed3
DB01229Paclitaxel1 / 2Recruiting2
DB01229Paclitaxel1 / 2Terminated1
DB09073Palbociclib1 / 2Recruiting1
DB00019Pegfilgrastim1 / 2Completed1
DB09037Pembrolizumab1 / 2Active Not Recruiting2
DB09037Pembrolizumab1 / 2Not Yet Recruiting1
DB06366Pertuzumab1 / 2Completed2
DB00811Ribavirin1 / 2Terminated1
DB08877Ruxolitinib1 / 2Active Not Recruiting1
DB08877Ruxolitinib1 / 2Recruiting1
DB12275Seviteronel1 / 2Recruiting1
DB00398Sorafenib1 / 2Active Not Recruiting1
DB00398Sorafenib1 / 2Completed1
DB00398Sorafenib1 / 2Unknown Status1
DB01268Sunitinib1 / 2Terminated1
DB00072Trastuzumab1 / 2Active Not Recruiting3
DB00072Trastuzumab1 / 2Not Yet Recruiting1
DB00072Trastuzumab1 / 2Recruiting1
DB00072Trastuzumab1 / 2Terminated3
DB05773Trastuzumab emtansine1 / 2Active Not Recruiting1
DB05773Trastuzumab emtansine1 / 2Completed2
DB05773Trastuzumab emtansine1 / 2Recruiting1
DB12170Veledimex1 / 2Active Not Recruiting1
DB00361Vinorelbine1 / 2Active Not Recruiting1
DB00361Vinorelbine1 / 2Unknown Status2
DB06080ABT-8692Completed1
DB12218AZD-53632Active Not Recruiting1
DB12001Abemaciclib2Active Not Recruiting2
DB08885Aflibercept2Completed1
DB12015Alpelisib2Recruiting1
DB06263Amrubicin2Withdrawn1
DB01217Anastrozole2Active Not Recruiting2
DB01217Anastrozole2Completed2
DB01217Anastrozole2Recruiting1
DB01217Anastrozole2Terminated2
DB01217Anastrozole2Unknown Status1
DB11595Atezolizumab2Active Not Recruiting1
DB11945Avelumab2Recruiting1
DB05051BZL1012Unknown Status1
DB00112Bevacizumab2Active Not Recruiting2
DB00112Bevacizumab2Completed11
DB00112Bevacizumab2Recruiting2
DB00112Bevacizumab2Terminated4
DB01128Bicalutamide2Recruiting1
DB00188Bortezomib2Terminated1
DB11666Buparlisib2Active Not Recruiting1
DB01101Capecitabine2Active Not Recruiting1
DB01101Capecitabine2Completed11
DB01101Capecitabine2Not Yet Recruiting1
DB01101Capecitabine2Recruiting2
DB01101Capecitabine2Terminated4
DB01101Capecitabine2Unknown Status5
DB00958Carboplatin2Active Not Recruiting3
DB00958Carboplatin2Completed6
DB00958Carboplatin2Recruiting1
DB00958Carboplatin2Terminated2
DB00002Cetuximab2Active Not Recruiting1
DB00002Cetuximab2Completed1
DB00515Cisplatin2Completed6
DB00515Cisplatin2Not Yet Recruiting1
DB00515Cisplatin2Recruiting1
DB00515Cisplatin2Terminated2
DB00515Cisplatin2Unknown Status1
DB05759Cixutumumab2Completed1
DB12250Cixutumumab2Completed1
DB09130Copper2Recruiting1
DB11672Curcumin2Recruiting1
DB00531Cyclophosphamide2Completed1
DB00531Cyclophosphamide2Recruiting2
DB00531Cyclophosphamide2Terminated2
DB11651Dactolisib2Withdrawn1
DB01254Dasatinib2Completed1
DB01234Dexamethasone2Completed1
DB08809Dichloroacetic Acid2Terminated1
DB00390Digoxin2Terminated1
DB00975Dipyridamole2Terminated1
DB00822Disulfiram2Recruiting1
DB01248Docetaxel2Active Not Recruiting1
DB01248Docetaxel2Completed13
DB01248Docetaxel2Recruiting1
DB01248Docetaxel2Terminated1
DB01248Docetaxel2Unknown Status1
DB05928Dovitinib2Terminated1
DB00997Doxorubicin2Completed5
DB00997Doxorubicin2Recruiting1
DB00997Doxorubicin2Terminated2
DB00997Doxorubicin2Unknown Status1
DB03516Eniluracil2Unknown Status1
DB12078Enobosarm2Completed1
DB08871Eribulin2Active Not Recruiting1
DB08871Eribulin2Completed2
DB08871Eribulin2Recruiting3
DB00530Erlotinib2Active Not Recruiting1
DB00530Erlotinib2Terminated1
DB00773Etoposide2Completed1
DB01590Everolimus2Active Not Recruiting1
DB01590Everolimus2Completed2
DB01590Everolimus2Not Yet Recruiting1
DB01590Everolimus2Recruiting1
DB00990Exemestane2Active Not Recruiting1
DB00990Exemestane2Completed2
DB00990Exemestane2Not Yet Recruiting1
DB00990Exemestane2Recruiting2
DB00990Exemestane2Withdrawn1
DB00099Filgrastim2Completed2
DB00544Fluorouracil2Completed1
DB00544Fluorouracil2Recruiting1
DB00544Fluorouracil2Unknown Status1
DB01185Fluoxymesterone2Terminated1
DB12396Fresolimumab2Active Not Recruiting1
DB00947Fulvestrant2Active Not Recruiting5
DB00947Fulvestrant2Completed6
DB00947Fulvestrant2Recruiting6
DB00947Fulvestrant2Terminated2
DB00947Fulvestrant2Unknown Status1
DB00317Gefitinib2Completed1
DB00441Gemcitabine2Active Not Recruiting1
DB00441Gemcitabine2Completed12
DB00441Gemcitabine2Not Yet Recruiting1
DB00441Gemcitabine2Recruiting1
DB00441Gemcitabine2Terminated1
DB00014Goserelin2Active Not Recruiting1
DB00014Goserelin2Completed1
DB00014Goserelin2Not Yet Recruiting2
DB00014Goserelin2Unknown Status2
DB00014Goserelin2Withdrawn1
DB11737Icotinib2Recruiting1
DB06370Indisulam2Terminated1
DB12827Indoximod2Active Not Recruiting1
DB11997Interleukin-72Completed1
DB00762Irinotecan2Active Not Recruiting1
DB12437Irosustat2Completed1
DB04845Ixabepilone2Completed8
DB04845Ixabepilone2Terminated2
DB04845Ixabepilone2Unknown Status1
DB01026Ketoconazole2Completed1
DB01259Lapatinib2Active Not Recruiting1
DB01259Lapatinib2Completed5
DB01259Lapatinib2Recruiting2
DB01259Lapatinib2Terminated5
DB01259Lapatinib2Unknown Status1
DB12984Larotaxel2Completed1
DB01006Letrozole2Active Not Recruiting2
DB01006Letrozole2Completed5
DB01006Letrozole2Not Yet Recruiting1
DB01006Letrozole2Recruiting3
DB00650Leucovorin2Completed1
DB00650Leucovorin2Unknown Status1
DB00007Leuprolide2Active Not Recruiting1
DB00007Leuprolide2Recruiting2
DB11861Litronesib2Completed1
DB06448Lonafarnib2Terminated1
DB11845Lucitanib2Active Not Recruiting1
DB00331Metformin2Completed1
DB00331Metformin2Terminated1
DB00563Methotrexate2Recruiting1
DB12117Mitometh2Recruiting1
DB00305Mitomycin2Recruiting1
DB09074Olaparib2Not Yet Recruiting1
DB09074Olaparib2Recruiting1
DB12066Orteronel2Recruiting1
DB00526Oxaliplatin2Completed3
DB00526Oxaliplatin2Terminated1
DB00526Oxaliplatin2Unknown Status3
DB01229Paclitaxel2Active Not Recruiting7
DB01229Paclitaxel2Completed16
DB01229Paclitaxel2Recruiting4
DB01229Paclitaxel2Terminated5
DB13809Paclitaxel poliglumex2Completed1
DB09073Palbociclib2Active Not Recruiting1
DB09073Palbociclib2Not Yet Recruiting1
DB09073Palbociclib2Recruiting8
DB01269Panitumumab2Completed1
DB00019Pegfilgrastim2Completed2
DB09037Pembrolizumab2Not Yet Recruiting2
DB09037Pembrolizumab2Recruiting1
DB00642Pemetrexed2Active Not Recruiting1
DB00642Pemetrexed2Recruiting1
DB06366Pertuzumab2Active Not Recruiting2
DB06366Pertuzumab2Completed1
DB12257Platinum2Recruiting1
DB12114Poziotinib2Active Not Recruiting1
DB12114Poziotinib2Recruiting1
DB11787Ralimetinib2Terminated1
DB12614Reparixin2Recruiting1
DB05626Retaspimycin2Terminated1
DB11730Ribociclib2Recruiting1
DB12332Rucaparib2Recruiting1
DB04996Satraplatin2Completed1
DB11857Seribantumab2Recruiting1
DB00398Sorafenib2Completed1
DB00398Sorafenib2Recruiting1
DB00398Sorafenib2Terminated1
DB01268Sunitinib2Completed1
DB01268Sunitinib2Terminated1
DB00675Tamoxifen2Active Not Recruiting1
DB00675Tamoxifen2Completed2
DB00675Tamoxifen2Recruiting2
DB00675Tamoxifen2Terminated1
DB00853Temozolomide2Active Not Recruiting2
DB12019Tesetaxel2Unknown Status1
DB04905Tesmilifene2Completed1
DB01041Thalidomide2Recruiting1
DB00072Trastuzumab2Active Not Recruiting4
DB00072Trastuzumab2Completed9
DB00072Trastuzumab2Not Yet Recruiting1
DB00072Trastuzumab2Recruiting2
DB00072Trastuzumab2Terminated3
DB00072Trastuzumab2Unknown Status3
DB05773Trastuzumab emtansine2Active Not Recruiting2
DB05773Trastuzumab emtansine2Completed3
DB11652Tucatinib2Not Yet Recruiting1
DB05558Upamostat2Completed1
DB05294Vandetanib2Completed1
DB05294Vandetanib2Recruiting1
DB12723Varlitinib2Completed1
DB07232Veliparib2Active Not Recruiting2
DB00460Verteporfin2Recruiting1
DB00570Vinblastine2Recruiting1
DB00541Vincristine2Recruiting1
DB00361Vinorelbine2Active Not Recruiting3
DB00361Vinorelbine2Completed4
DB00361Vinorelbine2Not Yet Recruiting1
DB00361Vinorelbine2Recruiting3
DB00361Vinorelbine2Terminated2
DB00361Vinorelbine2Unknown Status1
DB06629Zibotentan2Unknown Status1
DB05136Bavituximab2 / 3Suspended1
DB01101Capecitabine2 / 3Completed1
DB00958Carboplatin2 / 3Completed1
DB01248Docetaxel2 / 3Suspended1
DB00099Filgrastim2 / 3Terminated1
DB00441Gemcitabine2 / 3Completed1
DB01006Letrozole2 / 3Completed1
DB01229Paclitaxel2 / 3Completed1
DB01229Paclitaxel2 / 3Suspended1
DB09153Sodium Chloride2 / 3Terminated1
DB00072Trastuzumab2 / 3Terminated1
DB00361Vinorelbine2 / 3Terminated1
DB00399Zoledronic acid2 / 3Completed1
DB05812Abiraterone3Active Not Recruiting1
DB01217Anastrozole3Recruiting1
DB00112Bevacizumab3Active Not Recruiting1
DB00112Bevacizumab3Completed3
DB00112Bevacizumab3Unknown Status1
DB01101Capecitabine3Completed4
DB01101Capecitabine3Recruiting3
DB01101Capecitabine3Terminated2
DB01101Capecitabine3Unknown Status1
DB00958Carboplatin3Active Not Recruiting1
DB00958Carboplatin3Unknown Status1
DB00482Celecoxib3Completed1
DB06643Denosumab3Recruiting1
DB01248Docetaxel3Active Not Recruiting1
DB01248Docetaxel3Completed2
DB01248Docetaxel3Recruiting1
DB00997Doxorubicin3Active Not Recruiting1
DB00997Doxorubicin3Terminated1
DB00445Epirubicin3Completed1
DB08871Eribulin3Completed1
DB08871Eribulin3Recruiting2
DB01590Everolimus3Completed2
DB01590Everolimus3Recruiting1
DB01590Everolimus3Terminated1
DB00990Exemestane3Completed4
DB00990Exemestane3Recruiting3
DB00947Fulvestrant3Active Not Recruiting2
DB00947Fulvestrant3Completed1
DB00947Fulvestrant3Recruiting5
DB00441Gemcitabine3Completed1
DB00441Gemcitabine3Unknown Status1
DB00762Irinotecan3Unknown Status1
DB01259Lapatinib3Recruiting2
DB01259Lapatinib3Terminated1
DB01006Letrozole3Recruiting1
DB00351Megestrol acetate3Completed1
DB03209Oteracil3Terminated1
DB01229Paclitaxel3Active Not Recruiting4
DB01229Paclitaxel3Completed3
DB01229Paclitaxel3Recruiting3
DB01229Paclitaxel3Terminated1
DB09073Palbociclib3Active Not Recruiting1
DB09073Palbociclib3Recruiting2
DB06366Pertuzumab3Active Not Recruiting1
DB06366Pertuzumab3Recruiting1
DB00635Prednisone3Active Not Recruiting1
DB00675Tamoxifen3Recruiting1
DB00072Trastuzumab3Active Not Recruiting3
DB00072Trastuzumab3Completed2
DB00072Trastuzumab3Recruiting2
DB00072Trastuzumab3Terminated1
DB05773Trastuzumab emtansine3Completed1
DB07232Veliparib3Active Not Recruiting1
DB00361Vinorelbine3Completed2
DB00361Vinorelbine3Recruiting2
DB00958Carboplatin4Unknown Status1
DB00445Epirubicin4Unknown Status1
DB08871Eribulin4Recruiting1
DB01590Everolimus4Completed1
DB00947Fulvestrant4Active Not Recruiting1
DB01006Letrozole4Completed1
DB01006Letrozole4Terminated2
DB01229Paclitaxel4Unknown Status1
DB00399Zoledronic acid4Unknown Status1
DB12001AbemaciclibNot AvailableApproved for Marketing1
DB00112BevacizumabNot AvailableActive Not Recruiting1
DB01101CapecitabineNot AvailableCompleted1
DB01248DocetaxelNot AvailableCompleted1
DB11714DurvalumabNot AvailableActive Not Recruiting1
DB08871EribulinNot AvailableApproved for Marketing1
DB08871EribulinNot AvailableRecruiting1
DB01590EverolimusNot AvailableActive Not Recruiting1
DB00947FulvestrantNot AvailableRecruiting2
DB00279LiothyronineNot AvailableWithdrawn1
DB01229PaclitaxelNot AvailableActive Not Recruiting1
DB01229PaclitaxelNot AvailableCompleted1
DB09073PalbociclibNot AvailableCompleted1
DB06641PerifosineNot AvailableCompleted1
DB00675TamoxifenNot AvailableCompleted1
DB00072TrastuzumabNot AvailableCompleted1
DB05773Trastuzumab emtansineNot AvailableNo Longer Available1